Healthcare / BiotechnologyNYSE American
$1.30
-0.09 (-6.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-15.7M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$79M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-942.7%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-22.4M · FCF $-18.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Net Income | $-22.4M | $-22.4M | $-23.3M | $-19.8M | $-15.8M | $-12.6M |
| EBITDA | $-22.4M | $-22.4M | $-23.3M | $-19.8M | $-15.8M | — |
| EPS | — | — | -1.05 | -1.49 | -1.75 | -2.37 |
| Balance Sheet | ||||||
| Current Ratio | 5.59 | 5.59 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-18.8M | $-18.8M | $-15.7M | $-13.1M | $-12.1M | — |
| Returns | ||||||
| ROE | -942.7% | -942.7% | -639.8% | -4140.8% | -185.4% | — |
| Valuation | ||||||
| P/B | 21.13 | 21.13 | 13.62 | 41.94 | 3.83 | — |
| Growth & Yield | ||||||
| EPS Growth | — | — | 29.5% | 14.9% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.05 → n/d
Residual
-27.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.